Get the Stockscreener App
69.60
0.22%
0.15
After Hours:
69.60
Axonics Inc stock is traded at $69.60, with a volume of 413.58K.
It is up +0.22% in the last 24 hours and up +0.63% over the past month.
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.
See More
Previous Close:
$69.45
Open:
$69.1
24h Volume:
413.58K
Relative Volume:
1.23
Market Cap:
$3.56B
Revenue:
$408.81M
Net Income/Loss:
$-1.71M
P/E Ratio:
-278.40
EPS:
-0.25
Net Cash Flow:
$18.92M
1W Performance:
+0.85%
1M Performance:
+0.63%
6M Performance:
+0.91%
1Y Performance:
+24.02%
1-Day Range:
$69.10
$69.64
1-Week Range:
$68.95
$69.91
52-Week Range:
$48.30
$69.91
Axonics Inc Stock (AXNX) Company Profile
Name
Axonics Inc
Sector
Industry
Phone
949-396-6322
Address
26 TECHNOLOGY DRIVE, IRVINE, CA
Axonics Inc Stock (AXNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jul-13-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-23-23 | Initiated | CL King | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Upgrade | Needham | Hold → Buy |
| Oct-21-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Oct-10-22 | Downgrade | Needham | Buy → Hold |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jul-12-21 | Initiated | Barclays | Overweight |
| Jun-28-21 | Reiterated | Needham | Buy |
| Nov-05-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Aug-07-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Nov-01-19 | Initiated | Piper Jaffray | Overweight |
| Oct-21-19 | Initiated | Barclays | Overweight |
| Sep-17-19 | Initiated | SVB Leerink | Outperform |
| Sep-09-19 | Reiterated | Needham | Buy |
| Sep-03-19 | Initiated | Needham | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Nov-26-18 | Initiated | BofA/Merrill | Buy |
| Nov-26-18 | Initiated | Morgan Stanley | Overweight |
| Nov-26-18 | Initiated | SunTrust | Buy |
| Nov-26-18 | Initiated | Wells Fargo | Outperform |
View All
Axonics Inc Stock (AXNX) Latest News
Renaissance Technologies LLC Sells 140,200 Shares of Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
(AXNX) On The My Stocks Page - Stock Traders Daily
Squarepoint Ops LLC Purchases 185,809 Shares of Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device - Benzinga
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device - MSN
Axonics stock hits 52-week high at $69.91 amid robust growth - Investing.com
Dark Forest Capital Management LP Makes New Investment in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Axonics’ sacral neuromodulation device cleared in Australia - Medical Device Network
Axonics’ sacral neuromodulation device cleared in Australia - Yahoo Finance
Axonics, Inc. (NASDAQ:AXNX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia - StockTitan
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia - Business Wire
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic - MSN
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic - Yahoo Finance
Xponance Inc. Has $4.57 Million Stake in The AES Co. (NYSE:AES) - MarketBeat
Absolute Gestao de Investimentos Ltda. Makes New $32.68 Million Investment in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
AxoGen (NASDAQ:AXGN) Upgraded by StockNews.com to Buy - Defense World
Axos Financial, Inc. to Announce First Quarter Fiscal 2025 Results on October 30, 2024 - Business Wire
Wedbush Trims Axos Financial (NYSE:AX) Target Price to $75.00 - Defense World
Axos Financial price target lowered to $75 from $80 at Wedbush - TipRanks
Metric Deep Dive: Understanding AXT Inc (AXTI) Through its Ratios - The Dwinnex
Epoch Investment Partners Inc. Has $2.45 Million Stake in Axos Financial, Inc. (NYSE:AX) - MarketBeat
P Schoenfeld Asset Management LP Acquires 170,000 Shares of Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Glazer Capital LLC Invests $6.64 Million in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Raymond Cohen: Improving Patients’ Quality of Life - Orange County Business Journal
The top 10 urology device stories of 2024 so far - Mass Device
Hsbc Holdings PLC Raises Stock Position in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
First Eagle Investment Management LLC Has $12.21 Million Position in Axos Financial, Inc. (NYSE:AX) - Defense World
AxoGen, Inc. (NASDAQ:AXGN) Stock Holdings Lifted by Divisadero Street Capital Management LP - Defense World
Axos Financial, Inc. (NYSE:AX) Shares Sold by Edgestream Partners L.P. - MarketBeat
Axonics gains after win in trial in patent dispute with Medtronic - MSN
Axonics Prevalis Over Medtronic in Legal Dispute - MD+DI
Axonics Says Won Patent Case Against Medtronic - Orange County Business Journal
Axon stock soars to all-time high, reaching $391.32 - Investing.com
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit - Fierce Biotech
Jury sides with Axonics in Medtronic patent dispute - MedTech Dive
Axonics defeats Medtronic lawsuit in spine-stimulation patent trial - Reuters
Piper Sandler maintains Neutral rating on Axonics shares target post patent ruling - Investing.com
Jury says Axonics didn’t infringe on Medtronic patents - Mass Device
Jury Rules In Favor Of Axonics In Medtronic Patent Infringement Suit - MPO-mag
Jury sides with Axonics in Medtronic patent dispute - Yahoo Finance
J.W. Cole Advisors Inc. Invests $366,000 in Axon Enterprise, Inc. (NASDAQ:AXON) - Defense World
Axonics did not infringe Medtronic’s patents, jury rules - Medical Device Network
Axonics did not infringe Medtronic’s patents, jury rules - Yahoo Finance
Jury returns Medtronic’s patent infringement lawsuit against Axonics - Medical Buyer
Axonics prevails in patent infringement lawsuit with Medtronic - NeuroNews International
Axonics Didn't Infringe Medtronic Patents, Calif. Jury Says - Law360
Medtronic Loses Patent Trial Over Sacral-Nerve Implant Tech (1) - Bloomberg Law
Jury Finds Axonics Did Not Infringe Any of Three Patents-in-Suit - Morningstar
Jury Finds Axonics Did Not Infringe Any of Three Patents-in-Suit - MarketWatch
Axonics Prevails in Patent Infringement Lawsuit with Medtronic - The Bakersfield Californian
Axonics Inc Stock (AXNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):